Showing results (1-10 of 309) with videos related to
Sort By:
Pageof 31
Platelets|October 13, 2000
Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofurylI A Jagroop, D P MikhailidisJournal of Human Hypertension|September 12, 2000
Angiotensin II can induce and potentiate shape change in human platelets: effect of losartanI A Jagroop, D P MikhailidisPlatelets|August 12, 2000
An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal modelsI A Jagroop, D P MikhailidisJournal of Human Hypertension|April 24, 2001
Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human plateletsI A Jagroop, D P MikhailidisClinica Chimica Acta; International Journal of Clinical Chemistry|October 31, 1994
Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human plateletsM A Barradas, I A Jagroop, D P MikhailidisCurrent Pharmaceutical Design|June 23, 2007
Platelets and vascular risk: an option for treatmentI A Jagroop, A I Kakafika, D P MikhailidisBritish Journal of Clinical Pharmacology|February 1, 1996
A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregationI A Jagroop, M A Barradas, D P MikhailidisPlatelets|August 12, 2000
Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopyI A Jagroop, I Clatworthy, J Lewin, et al.International Journal of Cardiology|July 13, 1999
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular diseaseJ A Papadakis, E S Ganotakis, I A Jagroop, et al.American Journal of Hypertension|July 20, 1999
Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemiaJ A Papadakis, E S Ganotakis, I A Jagroop, et al.Pageof 31